FTC approves Novartis divestiture

The Federal Trade Commission gave final approval to Novartis’ divesting of assets related to its BRAF- and MEK-inhibitor drugs to satisfy the agency’s concerns that the drugmaker’s $16 billion acquisition of...

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:
Email: customerservices@mlex.com

Try FTCWatch FREE for 45 days

FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch

Current Issue: 1050
Next Issue: Jun 20, 2023

Browse Archives

In this Issue:

Khan being investigated by US House panel over abuse of power allegations
FTC’s Alexa settlement shows enforcement path for misuse of algorithmic data
DOJ, George’s Foods reach settlement over labor market abuses
Calendar
Auto dealers say Safeguards Rule needs tune-up
Let’s compare the 2024 election with the 1912 race
Noncompete rulemaking tab reported to Congress
On the Shelf: A payoff for more Americans
Court battles persist over regulating horseracing
People
FTC inspector general urges training on hiring expert witnesses
JetBlue’s overlaps with Spirit lessened by rejection of AA alliance, but logic of court ruling aids DOJ
Neil Averitt commentary: Amgen-Horizon case raises possibility of personalized merger law
Wu says FTC has law on its side
FTC typifies trend of disappearing commissioners, Wharton professors say
Parents’ pressure on legislators helping to change US privacy landscape
Judicial, political threats loom over FTC
Ex-Uber security chief’s sentence certain to lead to changes in cybersecurity industry
As FTC updates eyeglass rule, industry focuses on fallout
Calendar

RSS Feed